Toni Choueiri, MD, on Updated Follow-up Data in RCC at 2021 ASCO

Choueiri detailed combination treatments with follow-up data presented at the 2021 ASCO Annual Meeting.

Toni Choueiri, MD, of the Dana-Farber Cancer Institute, spoke with CancerNetwork® about trials of combination therapies that had updated data presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.


There were some studies that were not presented for the first time, but more analysis. So, KEYNOTE-426 [NCT02853331], for example, that [led to the approval of the combination] of pembrolizumab [Keytruda] and axitinib [Inlyta] now has a long median follow-up.

I think one of the issues with these VEGF/IO [immunotherapy] combinations [is that] they never have the same follow up as the IO/IO combinations like nivolumab [Opdivo]/ipilimumab [Yervoy]. Now, pembrolizumab/axitinib has more follow up [and it will] be interesting to look at the data in detail. There are data also for a newer combination of pembrolizumab/lenvatinib [Lenvima] that was presented a couple of months ago. There are data now about quality of life, we know this patient[-reported outcome].

There’s a lot of good stuff to be presented and I hope folks will follow all the data virtually that is coming in renal cell cancer, but also in [genitourinary] cancer in general.